Justice Department, DEA Propose Opioid Manufacturing Reduction in 2019

GoLocalProv News Team

Justice Department, DEA Propose Opioid Manufacturing Reduction in 2019

Justice Department, DEA propose opioid manufacturing reduction in 2019
The Department of Justice and U.S. Drug Enforcement Administration proposed a reduction for controlled substances that may be manufactured in the U.S. next year.

"The opioid epidemic that we are facing today is the worst drug crisis in American history. President Trump has set the ambitious goal of reducing opioid prescription rates by one-third in three years. We embrace that goal and are resolutely committed to reaching it. According to the National Prescription Audit, we have already made significant progress in reducing prescription rates over the past year. Cutting opioid production quotas by an average of ten percent next year will help us continue that progress and make it harder to divert these drugs for abuse. The American people can be confident that federal law enforcement and the Trump administration are taking action to protect them from dangerous drugs.  These smarter limits bring us one big step closer to President Trump's goal of finally ending this unprecedented crisis. I congratulate Acting Administrator Uttam Dhillon and his team for taking action,” said Attorney General Jeff Sessions.

The Proposal

GET THE LATEST BREAKING NEWS HERE -- SIGN UP FOR GOLOCAL FREE DAILY EBLAST

The proposal decreases manufacturing quotas for the most six frequently misused opioids for 2019 by an average ten percent as compared to the 2018 amount.

In setting the aggregate production quote (APQ), DEA considers data from many sources, including estimates of the legitimate medical need from the Food and Drug Administration; estimates of retail consumption based on prescriptions dispensed; manufacturers’ disposition history and forecasts; data from DEA’s own internal system for tracking controlled substance transactions; and past quota histories.

Once the aggregate quota is set, DEA allocates individual manufacturing and procurement quotas to those manufacturers that apply for them. DEA may revise a company’s quota at any time during the year if change is warranted due to increased or decreased sales or exports, new manufacturers entering the market, new product development, or product recalls.


RI Healthcare Disciplinary Actions August 2017- August 2018

Enjoy this post? Share it with others.